Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy

(2010) Jack Phan et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

(2010) L F Porrata et al.   LEUKEMIA

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

(2009) Isabelle Ray-Coquard et al.   CANCER RESEARCH

Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma

(2009) Toshiaki Morito et al.   CANCER SCIENCE

Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma

(2008) M. Christina Cox et al.   BRITISH JOURNAL OF HAEMATOLOGY

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab

(2008) Yasuhiro Oki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

(2008) K Stamatopoulos et al.   LEUKEMIA

Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

(2008) Dipti Talaulikar et al.   LEUKEMIA & LYMPHOMA

Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy

(2008) Yasuhiro Oki et al.   LEUKEMIA & LYMPHOMA

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

(2008) Maria Christina Cox et al.   LEUKEMIA & LYMPHOMA

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

(2007) E. Vellenga et al.   BLOOD